FGFR Inhibitor

Phase 2Small molecule

UUniversity Health Network, Toronto

FGFR Inhibitor is one of 16 small molecule programs targeting Bile Duct Carcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Bile Duct CarcinomaNot yet recruiting

Salivary Gland CancerActive, not recruiting

Bile Duct CarcinomaPhase 2

Not yet recruiting

Salivary Gland CancerPreclinical

Active, not recruiting

Competition

Competitive Landscape

17 competitors in Salivary Gland Cancer

#DrugCompanyPhaseTrials

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Approved

—2

Zoladex

TTerSera Therapeutics LLC

Keytruda

3 4

Alimta

EEagle Pharmaceuticals, Inc.

Phase 2

1 5

Navmi

SSummit Therapeutics

Phase 2

1 6

Pucotenlimab

SSun Yat-sen University

Phase 2

1 7

FGFR Inhibitor

UUniversity Health Network, Toronto

Phase 2

1 8

Xpovio

KKaryopharm Therapeutics Inc

Preclinical

1 9

Casodex

IIstituto Clinico Humanitas

Preclinical

1 10

Leuprorelin

Takeda

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2030

Phase 2Not yet recruiting

Bile Duct Carcinoma

NCT07729917

Clinical

Trials by Indication[1]

Salivary Gland Cancer1 trial

A Study of Drug Therapies for Salivary Gland Cancers Based on Testing of Genes

Completed·UUniversity Health Network, Toronto·N/A·NCT02069730·114 enrolled

Bile Duct Carcinoma1 trial

Precision Integrated Strategies and Efficacy Evaluation for Biliary Tract Cancers: An Umbrella Platform Study

Not yet recruiting·ZZhejiang University·Phase 2·NCT07729917·240 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for FGFR Inhibitor. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — FGFR Inhibitor compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for FGFR Inhibitor. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University Health Network, Toronto company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: UUniversity Health Network, Toronto

FGFR Inhibitor

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2030

Trials by Indication[1]

Salivary Gland Cancer1 trial

Bile Duct Carcinoma1 trial

References

Drug Info

Quick Facts

Related News